Table 4 Univariate and multivariate Cox Model for characteristics associated with progression-free survival in the EMD group only.
Variables | Progression-free survival | |||
|---|---|---|---|---|
Univariate analysis | Multivariable analysis | |||
HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
Age | ||||
<65 years | Ref. | |||
≥65 years | 1.05 (0.53–2.075) | 0.889 | ||
ECOG PS | ||||
0-1 | Ref. | Ref. | ||
≥2 | 3.36 (1.50–7.52) | 0.0032 | 3.90 (1.54–9.87) | 0.004 |
R-ISS | ||||
I | Ref. | |||
II | 2.33 (0.66–8.14) | 0.185 | ||
III | 0.68 (0.20–2.34) | 0.547 | ||
Cytogenetics by FISH | ||||
Standard risk | Ref. | |||
High risk | 1.46 (0.68–3.11) | 0.322 | ||
Bone marrow plasma cell burden | ||||
Low | Ref. | |||
High (>50% plasma cells) | 0.77 (0.33–1.81) | 0.559 | ||
Bridging therapy | ||||
No | Ref. | |||
Yes | 1.03 (0.43–2.46) | 0.947 | ||
Number of prior lines | ||||
4 | Ref. | Ref. | ||
>4 | 0.43 (0.19–1.009) | 0.052 | 0.22 (0.08–0.58) | 0.021 |
Penta-refractory | ||||
No | Ref. | Ref. | ||
Yes | 1.96 (1.02–3.76) | 0.042 | 1.91 (0.92–3.97) | 0.08 |
Prior anti-BCMA therapy | ||||
No | Ref. | Ref. | ||
Yes | 2.14 (0.95–4.80) | 0.065 | 7.72 (2.73–21.8) | 0.0001 |
CAR T-cell product | ||||
Ide-cel | Ref. | |||
Cilta-cel | 0.81 (0.33–1.95) | 0.646 | ||
Baseline CRP | ||||
Low | Ref. | |||
High | 1.41 (0.74–2.67) | 0.291 | ||
Baseline ferritin | ||||
Low | Ref. | |||
High | 1.45 (0.68–3.08) | 0.327 | ||
Number of EMD lesions | ||||
1–2 lesions | Ref. | |||
3 or more lesions | 1.14 (0.59–2.22) | 0.64 | ||
Presence of visceral EMD | ||||
No | Ref. | |||
Yes | 1.34 (0.71–2.54) | 0.359 | ||
Radiation therapy prior to CAR T | ||||
No | Ref. | Ref. | ||
Yes | 0.48 (0.24–0.95) | 0.037 | 0.39 (0.18–0.88) | 0.023 |
Lesion size | ||||
Lesion size ≤5 cm | Ref. | Ref. | ||
Lesion size >5 cm | 3.29 (1.32–8.51) | 0.0102 | 6.44 (2.14–19.33) | 0.0008 |
